Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams Against OP0595-Resistant Enterobacteriaceae Mutants

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2015 Nov 11

PMID 26552987

Citations 22

Authors

David M Livermore

Marina Warner

Shazad Mushtaq

Neil Woodford

Affiliations

Soon will be listed here.

Abstract

OP0595 is a novel diazabicyclooctane which, like avibactam, inhibits class A and C β-lactamases. In addition, unlike avibactam, it has antibacterial activity, with MICs of 0.5 to 4 μg/ml for most members of the family Enterobacteriaceae, owing to inhibition of PBP2; moreover, it acts synergistically with PBP3-active β-lactams independently of β-lactamase inhibition, via an "enhancer effect." Enterobacteriaceae mutants stably resistant to 16 μg/ml OP0595 were selected on agar at frequencies of approximately 10(-7). Unsurprisingly, OP0595 continued to potentiate substrate β-lactams against mutants derived from Enterobacteriaceae with OP0595-inhibited class A and C β-lactamases. Weaker potentiation of partners, especially aztreonam, cefepime, and piperacillin--less so meropenem--remained frequent for OP0595-resistant Enterobacteriaceae mutants lacking β-lactamases or with OP0595-resistant metallo-β-lactamases (MBLs), indicating that the enhancer effect is substantially retained even when antibiotic activity is lost.

Citing Articles

Rapid Emergence of Resistance to Broad-Spectrum Direct Antimicrobial Activity of Avibactam.

Nageli M, Rodriguez S, Manson A, Earl A, Brennan-Krohn T bioRxiv. 2024; .

PMID: 39386481 PMC: 11463622. DOI: 10.1101/2024.09.25.615047.

Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of β-lactams and the novel β-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging....

Blanco-Martin T, Lopez-Hernandez I, Aracil B, Gonzalez-Pinto L, Aja-Macaya P, Alonso-Garcia I Antimicrob Agents Chemother. 2024; 68(11):e0092424.

PMID: 39382274 PMC: 11539232. DOI: 10.1128/aac.00924-24.

Antibiotics in the clinical pipeline as of December 2022.

Butler M, Henderson I, Capon R, Blaskovich M J Antibiot (Tokyo). 2023; 76(8):431-473.

PMID: 37291465 PMC: 10248350. DOI: 10.1038/s41429-023-00629-8.

Penicillin-Binding Protein 5/6 Acting as a Decoy Target in Pseudomonas aeruginosa Identified by Whole-Cell Receptor Binding and Quantitative Systems Pharmacology.

Lopez-Arguello S, Montaner M, Sayed A, Oliver A, Bulitta J, Moya B Antimicrob Agents Chemother. 2023; 67(6):e0160322.

PMID: 37199612 PMC: 10269149. DOI: 10.1128/aac.01603-22.

Chemical Basis of Combination Therapy to Combat Antibiotic Resistance.

Si Z, Pethe K, Chan-Park M JACS Au. 2023; 3(2):276-292.

PMID: 36873689 PMC: 9975838. DOI: 10.1021/jacsau.2c00532.

References

Neu J . Synergy of mecillinam, a beta-amidinopenicillanic acid derivative, combined with beta-lactam antibiotics. Antimicrob Agents Chemother. 1976; 10(3):535-42. PMC: 429784. DOI: 10.1128/AAC.10.3.535. View

Barbour A, Mayer L, Spratt B . Mecillinam resistance in Escherichia coli: dissociation of growth inhibition and morphologic change. J Infect Dis. 1981; 143(1):114-21. DOI: 10.1093/infdis/143.1.114. View

Fass R . Activity of mecillinam alone and in combination with other beta-lactam antibiotics. Antimicrob Agents Chemother. 1980; 18(6):906-12. PMC: 352987. DOI: 10.1128/AAC.18.6.906. View

ISENBERG H, Cleeland R, TITSWORTH E, Beskid G, Christenson J, DELORENZO W . Correlation of the results of antibiotic synergy and susceptibility testing in vitro with results in experimental mouse infections. Crit Rev Microbiol. 1982; 10(1):1-76. DOI: 10.3109/10408418209113505. View

Anderson J, Eftekhar F . Study of the enhancement of beta-lactam activity by amdinocillin in a model of the human urinary bladder. Am J Med. 1983; 75(2A):42-7. DOI: 10.1016/0002-9343(83)90092-x. View

Eng R, Liu R, Smith S, Johnson E, CHERUBIN C . Amdinocillin: interaction with other beta-lactam antibiotics for gram-negative bacteria. Chemotherapy. 1988; 34(1):18-26. DOI: 10.1159/000238542. View

Sumita Y, Fukasawa M, Okuda T . Comparison of two carbapenems, SM-7338 and imipenem: affinities for penicillin-binding proteins and morphological changes. J Antibiot (Tokyo). 1990; 43(3):314-20. DOI: 10.7164/antibiotics.43.314. View

Petit A, Sofer L, Labia R . Characterization of chromosomally encoded penicillinases in clinical isolates of Klebsiella pneumoniae. J Antimicrob Chemother. 1992; 29(6):629-38. DOI: 10.1093/jac/29.6.629. View

Thevenet D, Dari R . ppGpp concentration, growth without PBP2 activity, and growth-rate control in Escherichia coli. Mol Microbiol. 1994; 13(5):911-7. DOI: 10.1111/j.1365-2958.1994.tb00482.x. View

10.

Sumita Y, Fukasawa M . Potent activity of meropenem against Escherichia coli arising from its simultaneous binding to penicillin-binding proteins 2 and 3. J Antimicrob Chemother. 1995; 36(1):53-64. DOI: 10.1093/jac/36.1.53. View

11.

Mushtaq S, Warner M, Williams G, Critchley I, Livermore D . Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother. 2010; 65(7):1428-32. DOI: 10.1093/jac/dkq161. View

12.

Livermore D, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M . Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2010; 55(1):390-4. PMC: 3019623. DOI: 10.1128/AAC.00756-10. View

13.

Livermore D, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N . What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents. 2011; 37(5):415-9. DOI: 10.1016/j.ijantimicag.2011.01.012. View

14.

Kahlmeter G, Poulsen H . Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: the ECO·SENS study revisited. Int J Antimicrob Agents. 2011; 39(1):45-51. DOI: 10.1016/j.ijantimicag.2011.09.013. View

15.

Livermore D, Mushtaq S, Morinaka A, Ida T, Maebashi K, Hope R . Activity of carbapenems with ME1071 (disodium 2,3-diethylmaleate) against Enterobacteriaceae and Acinetobacter spp. with carbapenemases, including NDM enzymes. J Antimicrob Chemother. 2012; 68(1):153-8. DOI: 10.1093/jac/dks350. View

16.

Shlaes D . New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann N Y Acad Sci. 2013; 1277:105-14. DOI: 10.1111/nyas.12010. View

17.

Ehmann D, Jahic H, Ross P, Gu R, Hu J, Durand-Reville T . Kinetics of avibactam inhibition against Class A, C, and D β-lactamases. J Biol Chem. 2013; 288(39):27960-71. PMC: 3784710. DOI: 10.1074/jbc.M113.485979. View

18.

Thulin E, Sundqvist M, Andersson D . Amdinocillin (Mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli. Antimicrob Agents Chemother. 2015; 59(3):1718-27. PMC: 4325821. DOI: 10.1128/AAC.04819-14. View

19.

Castanheira M, Mills J, Costello S, Jones R, Sader H . Ceftazidime-avibactam activity tested against Enterobacteriaceae isolates from U.S. hospitals (2011 to 2013) and characterization of β-lactamase-producing strains. Antimicrob Agents Chemother. 2015; 59(6):3509-17. PMC: 4432207. DOI: 10.1128/AAC.00163-15. View

20.

Morinaka A, Tsutsumi Y, Yamada M, Suzuki K, Watanabe T, Abe T . OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'. J Antimicrob Chemother. 2015; 70(10):2779-86. DOI: 10.1093/jac/dkv166. View